ISDA: 8QW7

Deposition Date 2023-10-18

Release Date 2023-12-06

Last Version Date 2024-10-02

Entry Detail

PDB ID:

8QW7

Keywords:

ONCOPROTEIN

Title:

Crystal Structure of compound 4 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.36 Å

R-Value Free:

0.27

R-Value Work:

0.24

R-Value Observed:

0.24

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:GTPase KRas
Gene (Uniprot):KRAS
Mutagens:G12V, C118S
Chain IDs:G (auth: A), H (auth: E)
Chain Length:170
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P01116 Pfam ID:PF00071 EC:3.6.5.2

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:von Hippel-Lindau disease tumor suppressor
Gene (Uniprot):VHL
Mutagens:Delta 1-53
Chain IDs:C (auth: B), F
Chain Length:162
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P40337 Pfam ID:PF01847, PF17211 EC:2.3.2.B13

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Elongin-C
Gene (Uniprot):ELOC
Mutagens:delta 1-16
Chain IDs:B (auth: C), E (auth: G)
Chain Length:97
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q15369 Pfam ID:PF03931

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Elongin-B
Gene (Uniprot):ELOB
Mutagens:delta 105-118
Chain IDs:A (auth: D), D (auth: H)
Chain Length:104
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q15370 Pfam ID:PF00240

Ligand Molecules

GDP

X53

Primary Citation

Targeting cancer with small-molecule pan-KRAS degraders.

Popow, J, Farnaby, W, Gollner, A, Kofink, C, Fischer, G, Wurm, M, Zollman, D, Wijaya, A, Mischerikow, N, Hasenoehrl, C, Prokofeva, P, Arnhof, H, Arce-Solano, S, Bell, S, Boeck, G, Diers, E, Frost, A.B, Goodwin-Tindall, J, Karolyi-Oezguer, J, Khan, S, Klawatsch, T, Koegl, M, Kousek, R, Kratochvil, B, Kropatsch, K, Lauber, A.A, McLennan, R, Olt, S, Peter, D, Petermann, O, Roessler, V, Stolt-Bergner, P, Strack, P, Strauss, E, Trainor, N, Vetma, V, Whitworth, C, Zhong, S, Quant, J, Weinstabl, H, Kuster, B, Ettmayer, P, Ciulli, A, Popow, J, Farnaby, W, Gollner, A, Kofink, C, Fischer, G, Wurm, M, Zollman, D, Wijaya, A, Mischerikow, N, Hasenoehrl, C, Prokofeva, P, Arnhof, H, Arce-Solano, S, Bell, S, Boeck, G, Diers, E, Frost, A, Goodwin-Tindall, J, Karolyi-Oezguer, J, Khan, S, Klawatsch, T, Koegl, M, Kousek, R, Kratochvil, B, Kropatsch, K, Lauber, A, McLennan, R, Olt, S, Peter, D, Petermann, O, Roessler, V, Stolt-Bergner, P, Strack, P, Strauss, E, Trainor, N, Vetma, V, Whitworth, C, Zhong, S, Quant, J, Weinstabl, H, Kuster, B, Ettmayer, P, Ciulli, A.Show

Science 385 1338 1347 (2024)

PMID: 39298590 DOI: 10.1126/science.adm8684

Abstact

Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein are highly prevalent in cancer. However, small-molecule concepts that address oncogenic KRAS alleles remain elusive beyond replacing glycine at position 12 with cysteine (G12C), which is clinically drugged through covalent inhibitors. Guided by biophysical and structural studies of ternary complexes, we designed a heterobifunctional small molecule that potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles. Compared with inhibition, KRAS degradation results in more profound and sustained pathway modulation across a broad range of KRAS mutant cell lines, killing cancer cells while sparing models without genetic KRAS aberrations. Pharmacological degradation of oncogenic KRAS was tolerated and led to tumor regression in vivo. Together, these findings unveil a new path toward addressing KRAS-driven cancers with small-molecule degraders.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form